Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Sees Large Increase in Short Interest

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the recipient of a significant increase in short interest in February. As of February 15th, there was short interest totalling 2,520,000 shares, an increase of 43.2% from the January 31st total of 1,760,000 shares. Currently, 6.9% of the shares of the stock are sold short. Based on an average daily volume of 6,070,000 shares, the days-to-cover ratio is presently 0.4 days.

Institutional Trading of Cardio Diagnostics

Hedge funds have recently made changes to their positions in the business. Two Sigma Securities LLC bought a new stake in Cardio Diagnostics during the fourth quarter worth approximately $48,000. Jane Street Group LLC purchased a new position in shares of Cardio Diagnostics in the 4th quarter worth approximately $103,000. Millennium Management LLC purchased a new position in shares of Cardio Diagnostics in the 4th quarter worth approximately $236,000. Finally, Geode Capital Management LLC raised its holdings in Cardio Diagnostics by 97.6% during the 4th quarter. Geode Capital Management LLC now owns 364,387 shares of the company’s stock valued at $334,000 after buying an additional 179,978 shares during the period. 8.06% of the stock is currently owned by hedge funds and other institutional investors.

Cardio Diagnostics Price Performance

Cardio Diagnostics stock traded down $0.03 during mid-day trading on Monday, reaching $0.42. 923,445 shares of the company’s stock traded hands, compared to its average volume of 3,089,781. Cardio Diagnostics has a 12-month low of $0.19 and a 12-month high of $1.79. The stock has a 50 day moving average of $0.64 and a two-hundred day moving average of $0.47.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.